By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Developing novel targeted oncology therapies and offering RenovoCath delivery system as stand-alone1.12M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States1.12M100.00%